Destiny 5 (B60)
NCT04622319
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy
Status:
Opening Soon
III
Phase
Line of Therapy
Early Cancer
Disease Stage
Biomarker(s)
HER2+
Investigational
Product
trastuzumab deruxtecan
Treatment Arms
o Trastuzumab deruxtecan
o Trastuzumab ematansine